Valiant Laboratories Limited
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The c… Read more
Valiant Laboratories Limited (VALIANTLAB) - Net Assets
Latest net assets as of September 2025: ₹3.17 Billion INR
Based on the latest financial reports, Valiant Laboratories Limited (VALIANTLAB) has net assets worth ₹3.17 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹4.25 Billion) and total liabilities (₹1.07 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹3.17 Billion |
| % of Total Assets | 74.73% |
| Annual Growth Rate | 27.53% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 59.92 |
Valiant Laboratories Limited - Net Assets Trend (2021–2025)
This chart illustrates how Valiant Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Valiant Laboratories Limited (2021–2025)
The table below shows the annual net assets of Valiant Laboratories Limited from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹2.34 Billion | -1.08% |
| 2024-03-31 | ₹2.37 Billion | +135.70% |
| 2023-03-31 | ₹1.00 Billion | +40.63% |
| 2022-03-31 | ₹714.60 Million | -19.33% |
| 2021-03-31 | ₹885.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Valiant Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹498.81 Million | 21.29% |
| Common Stock | ₹434.50 Million | 18.54% |
| Other Comprehensive Income | ₹1.91 Billion | 81.46% |
| Total Equity | ₹2.34 Billion | 100.00% |
Valiant Laboratories Limited Competitors by Market Cap
The table below lists competitors of Valiant Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
D G Khan Cement Company Ltd
KAR:DGKC
|
$5.31K |
|
Yoshi Innovation SA
WAR:YOS
|
$5.31K |
|
Autodrome PLC
CM:AUTON0000
|
$5.31K |
|
Misitano & Stracuzzi S.p.A.
F:O7E
|
$5.31K |
|
Phonic Corporation
TWO:3067
|
$5.31K |
|
Character Group
LSE:CCT
|
$5.30K |
|
EOI Holding
TW:3717
|
$5.30K |
|
EFU Life Assurance Ltd
KAR:EFUL
|
$5.29K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Valiant Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,368,612,000 to 2,343,101,000, a change of -25,511,000 (-1.1%).
- Net loss of 22,012,000 reduced equity.
- Other comprehensive income increased equity by 1,908,601,000.
- Other factors decreased equity by 1,912,100,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-22.01 Million | -0.94% |
| Other Comprehensive Income | ₹1.91 Billion | +81.46% |
| Other Changes | ₹-1.91 Billion | -81.61% |
| Total Change | ₹- | -1.08% |
Book Value vs Market Value Analysis
This analysis compares Valiant Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.94x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.50x to 0.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | ₹20.39 | ₹50.98 | x |
| 2022-03-31 | ₹16.45 | ₹50.98 | x |
| 2023-03-31 | ₹23.13 | ₹50.98 | x |
| 2024-03-31 | ₹62.32 | ₹50.98 | x |
| 2025-03-31 | ₹54.29 | ₹50.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Valiant Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.59%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.71x
- Recent ROE (-0.94%) is below the historical average (20.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 34.54% | 16.78% | 1.72x | 1.20x | ₹217.35 Million |
| 2022 | 38.48% | 9.43% | 1.60x | 2.54x | ₹203.50 Million |
| 2023 | 28.86% | 8.68% | 1.57x | 2.12x | ₹189.49 Million |
| 2024 | 0.13% | 0.18% | 0.53x | 1.45x | ₹-233.67 Million |
| 2025 | -0.94% | -1.59% | 0.35x | 1.71x | ₹-256.32 Million |
Industry Comparison
This section compares Valiant Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Valiant Laboratories Limited (VALIANTLAB) | ₹3.17 Billion | 34.54% | 0.34x | $5.31K |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |